The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus
Not Applicable
Completed
- Conditions
- non-alcoholic fatty liver disease/type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000013048
- Lead Sponsor
- Sapporo Kosei General Hospital, Department of Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) intake more than 20g/day of ethanol 2) HBsAg and/or HCV Ab positive 3) history of hepatic disease, such as autoimmune liver disease, hemochromatosis and Wilson's disease 4) history of diabetes ketosis and/or diabetic coma 5) during pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in liver stiffness
- Secondary Outcome Measures
Name Time Method improvement in physical findings and laboratory data
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie teneligliptin's efficacy in NAFLD with type 2 diabetes mellitus?
How does teneligliptin compare to other DPP-4 inhibitors in improving hepatic steatosis and glycemic control in T2DM patients with NAFLD?
Which biomarkers are associated with teneligliptin response in patients with NAFLD and type 2 diabetes mellitus?
What are the potential adverse events of teneligliptin in NAFLD patients with type 2 diabetes mellitus and how can they be managed?
Are there any combination therapies involving teneligliptin that show enhanced efficacy in treating non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus?